MARKET

CLRB

CLRB

Cellectar Biosciences Inc
NASDAQ
3.380
-0.030
-0.88%
After Hours: 3.389 +0.009 +0.27% 19:47 02/20 EST
OPEN
3.380
PREV CLOSE
3.410
HIGH
3.440
LOW
3.320
VOLUME
13.48K
TURNOVER
--
52 WEEK HIGH
20.59
52 WEEK LOW
2.450
MARKET CAP
14.33M
P/E (TTM)
-0.3137
1D
5D
1M
3M
1Y
5Y
1D
Cellectar Biosciences Announces Broad Expansion Of Its Global IP Estate, Including Newly Issued Patents Across Europe, Asia-Pacific, The Middle East, And The Americas
Benzinga · 4d ago
Cellectar Biosciences Secures New Patents to Strengthen Global Cancer Drug Portfolio
Reuters · 4d ago
Cellectar Biosciences Expands Global Intellectual Property Estate
Barchart · 4d ago
Weekly Report: what happened at CLRB last week (0209-0213)?
Weekly Report · 5d ago
Weekly Report: what happened at CLRB last week (0202-0206)?
Weekly Report · 02/09 10:19
Weekly Report: what happened at CLRB last week (0126-0130)?
Weekly Report · 02/02 10:19
Weekly Report: what happened at CLRB last week (0119-0123)?
Weekly Report · 01/26 10:19
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 01/20 12:05
More
About CLRB
Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of drugs for treatment of cancer. The Company, through its phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its lead programs are: Iopofosine I 131 (iopofosine), a beta-emitting iodine-131-based program which has been studied extensively; CLR 121225, an actinium-225-based program; and CLR 121125, an iodine-125 Auger-emitting program. Iopofosine evaluation is ongoing in a Phase IIb study in r/r multiple myeloma and central nervous system lymphoma patients and the CLOVER-2 Phase Ib study for pediatric patients with high grade gliomas.

Webull offers Cellectar Biosciences Inc stock information, including NASDAQ: CLRB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLRB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CLRB stock methods without spending real money on the virtual paper trading platform.